Skip to Content
Merck
CN
  • Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.

Molecular therapy : the journal of the American Society of Gene Therapy (2000-11-18)
J A Howe, G W Demers, D E Johnson, S E Neugebauer, S T Perry, M T Vaillancourt, B Faha
ABSTRACT

The oncolytic effect of adenoviruses may provide an efficient means to destroy tumor tissue if viruses could be developed with sufficient selectivity and efficacy. In this report we have characterized several adenoviruses, each with different mutations in the E1 region, for selective cytopathic effect in tumor cells in vitro and for their ability to inhibit tumor growth in vivo. Of the E1 mutants tested, we have identified one, E1Adl01/07, which preferentially induces cytopathic effects in a range of tumor cells versus primary cells. In addition, E1Adl01/07 significantly inhibited tumor growth and increased survival of mice in several models of human cancer. These results suggest that E1Adl01/07 might serve as an effective cancer therapeutic, combining both selectivity and efficacy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Adenovirus Antibody, clone 20/11, clone 20/11, Chemicon®, from mouse
Sigma-Aldrich
Goat Anti-Mouse IgG Antibody, (H+L) FITC Conjugated, 2 mg/mL (after reconstitution), Chemicon®